JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has reiterated its Market Outperform rating for Aquestive Therapeutics, maintaining a price target of $9.
September 30, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Aquestive Therapeutics, maintaining a price target of $9.
The reiteration of a Market Outperform rating and a maintained price target of $9 by JMP Securities is a positive signal for investors, suggesting confidence in Aquestive Therapeutics' future performance. This could lead to increased investor interest and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100